| Vinay K. Puduvalli, M.D. |
Present Title & Affiliation
Primary Appointment
Bio Statement
Dr. Puduvalli is an Associate Professor and the Director of Clinical Research in the Department of Neuro-Oncology. He is actively involved in patient care, clinical trials, basic and translational science laboratory interests. His clinical effort is directed towards developing novel therapies for patients with primary brain tumors and specifically malignant gliomas and he is the principal investigator of several clinical trials directed against these tumors. His clinical and laboratory research interests focus on the fields of epigenetics and apoptosis; in this context, he has been leading several clinical trials of epigenetic therapies. His laboratory efforts are focused on: 1) understanding the role of epigenetics in brain tumor biology and translating these findings into new treatment options; 2) identifying means to accelerate tumor cell death by activating death pathways in brain tumors.
Education & Training
Degree-Granting Education | |
| 1989 | Bangalore Medical College, Bangalore, India, MD, Medicine |
Postgraduate Training | |
| 7/1996-6/1998 | Fellowship, Neuro-Oncology, M. D. Anderson Cancer Center, Houston, TX, Kurt Jaeckle, M.D. |
| 7/1993-6/1996 | Residency, Neurology, University of Texas Health Sciences Center, Houston, TX, James Grotta, M.D. |
| 7/1992-6/1993 | Internship, Internal Medicine, Texas Tech University, Amarillo, TX, Constantine Saadeh, M.D. |
| 9/1991-6/1992 | Doctoral student, Human Genetics and Molecular Biology, University of Texas, Medical Branch at Galveston, Galveston, TX, Louis Sordahl, Ph.D. |
| 12/1990-7/1991 | Clinical Fellowship, Psychiatry, National Institute of Mental Health & Neurosciences, Bangalore, India |
| 11/1990-12/1990 | Registrar in Neurosurgery, Neurosurgery, MS Ramalah Medical College Hospitals, Bangalore, India |
| 10/1989-4/1990 | Senior Houseman, Surgery, Church of South India Hospital, Bangalore, India |
Board Certifications
| 1/1999 | American Board of Psychiatry and Neurology |
Experience/Service
Academic Appointments
Administrative Appointments/Responsibilities
Honors and Awards
| 2008 | NCI Triennial Audit Award, UT M.D. Anderson Cancer Center |
| 2007 | Excellence in Protocol Research, UT M.D. Anderson Cancer Center |
| 2000 | Physician Scientist Award, UT M. D. Anderson Cancer Center |
| 1999 | Research Support Grant, University Cancer Foundation (Kleburg) Biomedical |
| 1997 | Fellowship Research Award, UT M. D. Anderson Cancer Center |
| 1996 | Resident Recognition Award and Scholarship, American Academy of Neurology |
| 1991 | Teaching Assistantship, Dept of Human Biological Chemistry and Genetics, UTMB |
| 1983 | Endowment Scholarship, Kamal A. Baliga Memorial |
| 1983 | Scholarship, National Brihad Bharatiya Samaj |
Professional Memberships
| American Academy of Neurology Member, 1/1993-present |
| American Association for Clinical Oncology (ASCO) Member, 1/1997-present |
| American Association of Cancer Research Member, 1/1997-present |
| Harris County Medical Society Member, 1/1993-present |
| Society of Neuro Oncology Member, 1/1997-present |
| Texas Medical Association Member, 1/1993-present |
Selected Publications
Peer-Reviewed Original Research Articles | ||
| 1. | Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 8/2009. PMID: 19672263. | |
| 2. | Groves, MD, Hess KR, Puduvalli V, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol, 3/2009. e-Pub 3/2009. PMID: 19267183. | |
| 3. | Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113(16). e-Pub 12/18/2008. PMCID: PMC2670791. | |
| 4. | de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 10/2008. e-Pub 6/2008. PMID: 18581057. | |
| 5. | Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK.. A Multicenter Phase II Trial of Intrathecal Topotecan in Patients with Meningeal Malignancies. Neuro Oncol 10(2):208-215, 1215/15228517-2007-059, 4/2008. e-Pub 3/2008. PMCID: PMC2613823. | |
| 6. | Puduvalli VK, Giglio P, Groves MD, Hess K, Gilbert MR, Mahankali S, Jackson E, Levin V, Conrad CA, Hsu S, Colman H, deGroot J, Ritterhouse MG, Ictech S, Yung WKA. Phase II trial of Irinotecan and Thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-222, DOI:10.1215/15228517-2007-060, 4/2008. e-Pub 2/2008. PMCID: PMC2613824. | |
| 7. | Kyritsis AP, Puduvalli VK, Levin VA. Chemotherapy as first line treatment for oligodendroglioma. J Neurooncol 86(3)(3):361-362, 2/2008. e-Pub 8/21/2007. PMID: 17710374. | |
| 8. | Kyritsis AP, Tachmazoglou F. Rao JS, Puduvalli VK. Temozolomide and resistant glioma cells. J Neurosurg 108(1):197, 1/2008. PMID: 18173334. | |
| 9. | Kyritsis AP, Rao JS, Puduvalli VK. Radio-responsive TRAIL gene therapy for malignant gliomas. Cancer Gene Ther 14(12)(12):1002, 12/2007. e-Pub 8/17/2007. PMID: 17704752. | |
| 10. | Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. (Int J Radiat Oncol Biol Phys 2007;69:820-824). Int J Radiat Oncol Biol Phys 69(4):1335; author reply 1335, 11/15/2007. PMID: 17967325. | |
| 11. | Kyritis AP, Tachmazoglou F, Rao JS, Puduvalli VK. Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clin Cancer Res 13(21)(21):6540-6541, 11/2007. PMID: 17975168. | |
| 12. | Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. Int J Radiat Oncol Biol Phys 69(4):820-824, 11/2007. | |
| 13. | Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271-7, 2/2007. e-Pub 9/22/2006. PMID: 17031561. | |
| 14. | Groves MD, Puduvalli VK, conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1)(1):83-90, 10/2006. e-Pub 4/25/2006. PMID: 16639492. | |
| 15. | Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-907, 8/2006. PMID: 16914578. | |
| 16. | Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1)(1):85-90, 5/2006. e-Pub 11/29/2005. PMID: 16391896. | |
| 17. | Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 65:1547-53, 2/2005. PMID: 15735044. | |
| 18. | Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-43, 2005. PMID: 15711939. | |
| 19. | Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22:4282-9, 11/2004. PMID: 15514370. | |
| 20. | Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4)(4):308-314, 10/2004. e-Pub 6/2004. PMID: 15184994. | |
| 21. | Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Pudavalli V, Levin VA, Yung WK, Wei Q. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 64:5560-3, 8/2004. PMID: 15313891. | |
| 22. | Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 117:307-336, 1/2004. PMID: 15015567. | |
| 23. | Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer 98:363-8, 7/2003. PMID: 12872358. | |
| 24. | Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259-66, 2003. PMID: 14657600. | |
| 25. | Herbst RS, Madden TL, Tran HT, Blumenschein GR, Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20:4440-7, 11/2002. PMID: 12431966. | |
| 26. | Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol 4:268-77, 10/2002. PMID: 12356357. | |
| 27. | Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383-8, 3/2002. PMID: 11870183. | |
| 28. | Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 3:467-75, 11/2001. PMID: 11595114. | |
| 29. | Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17(5):963-9, 11/2000. PMID: 11029499. | |
| 30. | Puduvalli VK, Sawaya R. Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189-200, 10/2000. PMID: 11245279. | |
| 31. | Saitoh Y, Goto T, Puduvalli VK, Murakami M, Kochi M, Levin VA, Kyritsis AP, Ushio Y. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. Int J Oncol 15:499-504, 9/1999. PMID: 10427131. | |
| 32. | Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 5:2230-5, 8/1999. PMID: 10473110. | |
| 33. | Puduvalli VK, Yung AW. New frontiers in therapy of malignant gliomas. Forum (Genova) 8:261-9, 7/1998. PMID: 9755291. | |
| 34. | Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12:665-9, 3/1998. PMID: 9472109. | |
| 35. | Puduvalli VK, Sella A, Austin SG, Forman AD. Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer 77:1189-92, 3/1996. PMID: 8635142. | |
Book Chapters | ||
| 1. | Puduvalli, VK. Aberrations of the epigenome in gliomas: Novel targets for therapy. In: Glioblastoma: Molecular mechanisms of pathogenesis and current therapeutic strategies. Ed(s) S.K. Ray. Springer -Verlag: New York, NY. In Press. | |
| 2. | Grunfeld J, Puduvalli V. Role of Brain Microenvironment in Brain Metastases. In: Integration/Interaction of Oncologic Growth, (Cancer Growth and Progression), 1. Ed(s) Gary Meadows. Springer: The Netherlands, 127-148, 2005. PMID: 140203413X. | |
| 3. | Puduvalli V. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. In: Angiogenesis in Brain Tumors (Cancer Treatment and Research). Springer: USA, 2004. PMID: 1402077041. | |
| 4. | Puduvalli V, Armstrong T. Management of patients with brain metastasis. In: Palliative Care Consultations - Primary and Metastatic Brain Tumours,. Ed(s) Booth S, Bruera E, Oliver D. Oxford University Press: USA, 2004. PMID: 0198528078. | |
| 5. | Puduvalli V. Neurogenetic syndromes associated with nervous system neoplasms. In: Atlas of Cancer. Ed(s) Maurie Markman. Lipincott Williams & Wilkins: USA, 607 – 616, 2002. | |
Grant & Contract Support
| Title: | Targeting Gliomas through Histone Deacetylase Inhibition |
| Funding Source: | NIH/NCI SPORE in Brain Cancer |
| Role: | DRP Awardee |
| Principal Investigator: | W.K.W. Yung, MD |
| Duration: | 9/1/2008 - 8/31/2010 |
| Title: | Strategies to Enhance Effects of Histone Deacetylase (HDAC) Inhibitors against Malignant Gliomas |
| Funding Source: | UTMDACC Center for Targeted Therapy |
| Role: | Principal Investigator |
| Duration: | 12/1/2007 - 11/30/2009 |
| Title: | Phase I/II trial of irinotecan plus lenalidomide in adult patients with recurrent glioblastoma multiforme (CT). |
| Funding Source: | Celgene Pharmaceuticals |
| Role: | Principal Investigator |
| Duration: | 9/26/2007 - 9/30/2010 |
| Title: | Phase I/II adaptive randomized trial of vorinostat, isotretinoin, carboplatin in adults with recurrent glioblastoma multiforme. |
| Funding Source: | Commonwealth Foundation Grant - MDACC Foundation |
| Role: | Principal Investigator |
| Duration: | 5/1/2007 - 5/1/2010 |
| Title: | Efficacy and toxicity of TRAIL against gliomas |
| Funding Source: | NIH/NCI 1RO1CA114422 |
| Role: | Principal Investigator |
| Duration: | 1/5/2006 - 12/31/2010 |
| Title: | Early Therapeutics Development with Phase II Emphasis (PC-A) |
| Funding Source: | NIH/NCI NO1-CM-62202 |
| Role: | Co-Investigator |
| Principal Investigator: | David Stewart |
| Duration: | 1/1/2006 - 12/31/2009 |
| Title: | Oncolytic adenovector mediated TRAIL gene therapy for cancers |
| Funding Source: | NIH/NCI 5RO1CA092487 |
| Role: | Co-Investigator |
| Principal Investigator: | Bingliang Fang |
| Duration: | 7/1/2001 - 1/31/2012 |
Last updated: 9/8/2009
- Global Navigation
- About Us
- Locations
- Events
- Careers
- Publications
- How You Can Help
- Contact Us
- Newsroom
- Site Index
- Patient & Cancer Information
- myMDAnderson
- Cancer Information
- Patient Information
- Care Centers & Clinics
- Children’s Cancer Hospital
- Services & Amenities
- Physician Directory
- Education and Research
- Departments, Programs & Labs
- PeopleFinder
- Research at M.D Anderson
- Education & Training
- Resources for Professionals
- For Employees
- Employee Alerts
- Employee Resources
- Doing Business
- Vendors & Suppliers
- Partners & Affiliates

